<DOC>
	<DOCNO>NCT01686698</DOCNO>
	<brief_summary>Probiotics , due ability modulate intestinal flora , intestinal permeability immune response , could decrease bacterial translocation improve immune system alteration cirrhosis . This could lead improvement liver function prevent bacterial infection complication also improve CD avoid consequence fall , HRQoL deterioration ) . Recently , investigator observe VSL # 3 administration rat experimental cirrhosis decrease bacterial translocation , inflammatory response ascites formation , without change intestinal flora . This suggest improvement intestinal barrier deserve investigation . VSL # 3 , decrease intestinal bacterial translocation immune system modulation , could improve cognitive function prevent consequence CD , include fall HRQoL deterioration , patient cirrhosis .</brief_summary>
	<brief_title>Effect VSL # 3 ( Original De Simone Formulation ) Cognitive Function , Risk Falls Quality Life Patients With Cirrhosis</brief_title>
	<detailed_description>OBJECTIVES Primary endpoint To assess effect VSL # 3 cognitive function patient cirrhosis . Secondary endpoint To assess effect VSL # 3 : - risk fall - HRQoL - incidence complication cirrhosis mortality study - metabolomics urine - endocannabinoid system ( MAGL FAAH enzymes ) - soluble CD163 blood index macrophage activation portal hypertension ( 39 ) - portal hypertension evaluate abdominal doppler ultrasonography PATIENTS AND METHODS Inclusion criterion Outpatients cirrhosis cognitive dysfunction and/or fall previous year visit Hospital de la Santa Creu Sant Pau . Cirrhosis diagnose clinical , analytical ultrasonographic finding liver biopsy . Exclusion criterion - Hospitalization previous month due decompensation cirrhosis . Hepatocellular carcinoma malignancy . - Active alcohol intake ( previous 3 month ) . - Current overt acute chronic hepatic encephalopathy . - Clinically significant cognitive impairment accord Short Portable Mental Status Questionnaire ( SPMSQ ) &gt; 5 point . - Neurological disease . - Inability perform psychometric test . - Marked symptomatic comorbidities ( cardiac , pulmonary , renal , untreated active depression ) . - Life expectancy le 6 month . - Treatment non-absorbable disaccharide . - Treatment antiviral drug . - Antibiotic treatment ( norfloxacin ) . Study Agent VSL # 3 probiotic mixture 8 proprietary strain , namely Streptococcus thermophilus , bifidobacteria ( B. breve , B. longum , B. infantis ) lactobacillus ( L. paracasei , L. acidophilus , L. delbrueckii subsp bulgaricus , L. plantarum ) . The active agent supply 4.4g sachet dose 450 billion live bacteria per sachet maltose silicon dioxide excipients . Placebo formulate identical appearance administer accord schedule active agent . Placebo contain maltose silicon dioxide inactive agent . VSL # 3 food supplement market Europe since 2002 . The study agent need keep refrigerated time . It may keep room temperature week without affect potency . Study agent supply Actial Farmaceutica Lda , Funchal ( Portugal ) Study design Double-blind placebo-controlled clinical trial . Forty consecutive patient cirrhosis CD ( PHES &lt; -4 ) and/or fall previous year randomize receive VSL # 3 , sachet contain 450 x 109 bacteria , 1 sachet every 12 hour 3 month ( n=20 ) , placebo ( n=20 ) . Patients randomly assign either active study agent placebo randomization list elaborate specific software supply Actial Farmaceutica Lda . The first box product ( 60 sachet ) give patient begin study . Patients instructed take dos , register miss dose bring back box next visit . Patients also instruct bring urine sample Falcon tube provide previous visit . Then , patient give back boxes receive next set product every month . The investigator count number remain sachet return box . Patients visit 0 , 4 , 6 , 8 , 12 20 week . ASSESSMENTS Patients visit 0 , 4 , 6 , 8 , 12 20 week . The following patient ' assessment perform .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Outpatients cirrhosis visit Hospital de la Santa Creu Sant Pau . Cirrhosis diagnose clinical , analytical ultrasonographic finding liver biopsy . Hospitalization previous month due decompensation cirrhosis . Hepatocellular carcinoma malignancy . Active alcohol intake ( previous 3 month ) . Current overt acute chronic hepatic encephalopathy . Clinically significant cognitive impairment accord Short Portable Mental Status Questionnaire ( SPMSQ ) &gt; 5 point . Neurological disease . Inability perform psychometric test . Marked symptomatic comorbidities ( cardiac , pulmonary , renal , untreated active depression ) . Life expectancy le 6 month . Treatment nonabsorbable disaccharide . Treatment antiviral drug . Antibiotic treatment ( norfloxacin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cirrhosis , VSL # 3 , cognitive function , fall , quality life</keyword>
</DOC>